Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopez-Berestein, G.
Right arrow Articles by Mehta, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez-Berestein, G.
Right arrow Articles by Mehta, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 5, 310-317, Copyright © 1987 by American Society of Clinical Oncology


ARTICLES

Treatment of hepatosplenic candidiasis with liposomal-amphotericin B

G Lopez-Berestein, GP Bodey, LS Frankel and K Mehta

Nine patients with hematologic malignancies developed fungal infections, predominantly involving the liver and spleen. Eight patients had biopsy-documented progressive candidiasis and one had an unclassified fungus. The patients were treated with liposomal- amphotericin B (L-AmpB) after their fungal infection progressed during treatment with standard intravenous (IV) AmpB (Fungizone; E. R. Squibb & Son, Princeton, NJ) and/or other antifungals. Eight patients (88.8%) were cured of their fungal infection, and one showed improvement after treatment. Minor acute toxicity and no chronic toxicity were associated with the administration of L-AmpB. L-AmpB is a safe and effective therapeutic method for treating fungal infections that have invaded the liver and spleen even when they are refractory to conventional anti- fungal therapy.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
M. T. N. Campanha, E. M. Mamizuka, and A. M. Carmona-Ribeiro
Interactions between cationic liposomes and bacteria: the physical-chemistry of the bactericidal action
J. Lipid Res., August 1, 1999; 40(8): 1495 - 1500.
[Abstract] [Full Text]


Home page
J Antimicrob ChemotherHome page
L. C. Souza and A. Campa
Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion
J. Antimicrob. Chemother., July 1, 1999; 44(1): 77 - 84.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. J. Levine, T. J. Walsh, A. Martinez, P. Q. Eichacker, G. Lopez-Berestein, and C. Natanson
Cardiopulmonary Toxicity after Liposomal Amphotericin B Infusion
Ann Intern Med, April 15, 1991; 114(8): 664 - 666.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
G. Lopez-Berestein, G. P. Bodey, V. Fainstein, M. Keating, L. S. Frankel, B. Zeluff, L. Gentry, and K. Mehta
Treatment of Systemic Fungal Infections With Liposomal Amphotericin B
Arch Intern Med, November 1, 1989; 149(11): 2533 - 2536.
[Abstract] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1987 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online